Marre 2002

1 Treatments

**Studied treatment**  nateglinide 60 mg, 120 mg before three meals

**Control treatment**  placebo

**Concomittant treatments**  metformin 1000 mg b.i.d.

2 Patients

**Patients**  metformin-treated patients with HbA1c between 6.8% and 11%

**Inclusion criteria**  -

**Exclusion criteria**  -

3 Methods

**Blinding**  double-blind

**Design**  Parallel groups

**Centers**  -

**Geographical area**  -

**Sizes**  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References

Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002;4:177-86 [12047396]